Organon & Co. (NYSE:OGN) Given Consensus Rating of “Reduce” by Brokerages

Shares of Organon & Co. (NYSE:OGN) have been assigned a consensus rating of “Reduce” from the seven analysts that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating and five have assigned a hold rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $11.40.

Several analysts recently weighed in on OGN shares. Piper Sandler upgraded shares of Organon & Co. from an “underweight” rating to a “neutral” rating and lifted their price objective for the company from $5.00 to $14.00 in a research report on Tuesday, April 28th. BNP Paribas Exane restated a “neutral” rating and issued a $14.00 price target (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Weiss Ratings raised Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, July 13th. Finally, Zacks Research upgraded Organon & Co. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 14th.

Insiders Place Their Bets

In other Organon & Co. news, SVP Lynette Holzbaur bought 26,448 shares of the business’s stock in a transaction on Wednesday, May 6th. The shares were purchased at an average price of $13.35 per share, with a total value of $353,080.80. Following the purchase, the senior vice president directly owned 52,851 shares of the company’s stock, valued at approximately $705,560.85. The trade was a 100.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 1.62% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Organon & Co. by 2.7% in the fourth quarter. Vanguard Group Inc. now owns 36,916,382 shares of the company’s stock worth $264,690,000 after purchasing an additional 987,979 shares during the period. State Street Corp increased its stake in Organon & Co. by 2.8% during the 4th quarter. State Street Corp now owns 9,597,761 shares of the company’s stock valued at $68,816,000 after buying an additional 262,185 shares during the period. AQR Capital Management LLC raised its position in shares of Organon & Co. by 105.2% during the 4th quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock worth $61,282,000 after buying an additional 4,394,814 shares in the last quarter. Private Management Group Inc. lifted its stake in shares of Organon & Co. by 38.3% in the 4th quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock worth $31,169,000 after acquiring an additional 1,204,979 shares during the period. Finally, UBS Group AG lifted its stake in shares of Organon & Co. by 55.2% in the 4th quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock worth $30,795,000 after acquiring an additional 1,527,492 shares during the period. 77.43% of the stock is owned by institutional investors and hedge funds.

Organon & Co. Stock Performance

OGN traded up $0.01 during trading on Thursday, reaching $13.54. 154,878 shares of the company were exchanged, compared to its average volume of 6,118,735. The stock has a market cap of $3.56 billion, a P/E ratio of 14.56, a PEG ratio of 1.25 and a beta of 1.54. The firm has a 50 day moving average of $13.47 and a 200 day moving average of $10.34. The company has a current ratio of 1.97, a quick ratio of 1.42 and a debt-to-equity ratio of 9.47. Organon & Co. has a 52 week low of $5.69 and a 52 week high of $13.60.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, April 30th. The company reported $0.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.83 by ($0.12). Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period last year, the firm posted $1.02 EPS. The business’s revenue was down 3.5% compared to the same quarter last year. On average, sell-side analysts forecast that Organon & Co. will post 3.23 EPS for the current fiscal year.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.